Amgen stock climbs on cancer drug promise

EARLY RESULTS FROM early results from an experimental therapy developed by Amgen showed promise in colon cancer. / BLOOMBERG FILE PHOTO
EARLY RESULTS FROM early results from an experimental therapy developed by Amgen showed promise in colon cancer. / BLOOMBERG FILE PHOTO
NEW YORK – Shares of Amgen Inc. rose as much as 2.3% in pre-market trading after early results from an experimental therapy showed promise in colon cancer and drew attention away from earnings and fears about the company’s aging portfolio. “AMG510 steals the show,” RBC analyst Kennen MacKay wrote in a note to clients while still…

Want More?

Subscribe or register with Providence Business News to keep reading.

REGISTER
for 2 more stories

Subscribe now for $1 for 4 weeks
Already a Subscriber? Login now

Purchase NowWant to share this story? Click Here to purchase a link that allows anyone to read it on any device whether or not they are a subscriber.

- Advertisement -

No posts to display